

For Immediate Release

Melbourne, Australia — 22 July 2010


Royalties from Relenza for Q4 and F2010

Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties from Relenza were \$0.9m during the three months ended 30 June 2010, on sales of \$12.8m.

Indicative royalties and sales advised by GSK, by quarter are summarised below:

	Q1	Q2	Q3	Q4	Total
Indicative royalties \$m	24.1	32.6	9.7	0.9	67.3
Indicative sales \$m	331	462	138	13	944

Biota will report actual royalties from Relenza of \$63.7m for the year to 30 June 2010, which differs from the cumulative indicative royalties previously announced due to exchange rate differences at the end of each quarter compared to the rate applicable on the payment date.



Biota notes that at \$63.7 million F2010 is a record year for Relenza royalties, since the product was launched in 1999/2000, as a result of demand driven by the 09H1N1 swine flu pandemic and consequent increased production by GSK.

Influenza in both its seasonal and pandemic forms has proven to be quite unpredictable, making future sales or royalty forecasts difficult. The increase in annual manufacturing capacity by GSK to 90 million courses should ensure that in future higher peak demands can be met, should the need arise.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product laninamivir, is in late stage clinical development.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

*Further information available at www.biota.com.au

Investor / Analyst Enquiries

Biota Holdings Limited

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Media Enquiries

Jo Lynch, Hinton & Associates

T: +61 3 9600 1979 / M: +61 411 208 101

US Enquiries

Remy Bernarda, Blueprint Life Science Group

M: +1 415 203 6386